[HTML][HTML] Pre-Treatment With Oral P2Y12 Inhibitors in Acute Coronary Syndromes Without ST-Segment Elevation: The Saga Continues
D Capodanno, DJ Angiolillo - Journal of the American College of …, 2019 - jacc.org
(ACS), the term “pre-treatment” usually refers to the practice of initiating dual antiplatelet
therapy, in particular an oral P2Y12 inhibitor in adjunct to aspirin, before performing the …
therapy, in particular an oral P2Y12 inhibitor in adjunct to aspirin, before performing the …
Pretreatment With P2Y12 Inhibitors in Non–ST-Segment–Elevation Acute Coronary Syndrome Is Clinically Justified
M Valgimigli - Circulation, 2014 - Am Heart Assoc
1892 Circulation November 18, 2014 who were hospitalized within 24 hours after the onset
of symptoms. 9 A loading dose of clopidogrel (300 mg) or placebo was administered …
of symptoms. 9 A loading dose of clopidogrel (300 mg) or placebo was administered …
[HTML][HTML] Pre-Treatment With Oral P2Y12 Inhibitors in Non–ST-Segment Elevation Acute Coronary Syndromes: Does One Size Fit All?
JL Ferreiro - Cardiovascular Interventions, 2020 - jacc.org
The value of pre-treatment with an oral P2Y12 receptor inhibitor (in addition to aspirin), that
is, its administration prior to coronary angiography and defining the coronary anatomy, in …
is, its administration prior to coronary angiography and defining the coronary anatomy, in …
[HTML][HTML] Potent P2Y12 Inhibitors in Low-Risk Patients: Is There a Medical Need?
The oral P2Y12 inhibitors prasugrel and ticagrelor have demonstrated biological and clinical
superiority over clopidogrel, with a faster onset of action and greater potency, which …
superiority over clopidogrel, with a faster onset of action and greater potency, which …
[HTML][HTML] Non-ST-segment elevation acute coronary syndrome: the last nail in the coffin of pre-treatment
G Montalescot - Journal of the American College of Cardiology, 2020 - jacc.org
Pre-treatment with an oral P2Y12 receptor inhibitor in addition to aspirin is defined by its
administration to every patient before coronary angiography, which will (or not) confirm the …
administration to every patient before coronary angiography, which will (or not) confirm the …
Pretreatment with prasugrel in non–ST-segment elevation acute coronary syndromes
G Montalescot, L Bolognese, D Dudek… - … England Journal of …, 2013 - Mass Medical Soc
Background Although P2Y12 antagonists are effective in patients with non–ST-segment
elevation (NSTE) acute coronary syndromes, the effect of the timing of administration …
elevation (NSTE) acute coronary syndromes, the effect of the timing of administration …
Timing of Oral P2Y12 Inhibitor Administration in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome
G Tarantini, M Mojoli, F Varbella, R Caporale… - Journal of the American …, 2020 - jacc.org
Abstract Background Although oral P2Y12 inhibitors are key in the management of patients
with non–ST-segment elevation acute coronary syndrome, the optimal timing of their …
with non–ST-segment elevation acute coronary syndrome, the optimal timing of their …
The differences between the guidelines of the European Society of Cardiology and the American College of Cardiology/American Heart Association for oral P2Y12 …
VL Serebruany, IV Pershukov - Kardiologiia, 2013 - europepmc.org
The analysis of the evidence that formed the basis for the current guidelines of the European
Society of Cardiology (ESC) on oral therapy by antithrombotic drugs for acute coronary …
Society of Cardiology (ESC) on oral therapy by antithrombotic drugs for acute coronary …
2020 ESC Guidelines for: Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation
N Karia - 2020 - britishcardiovascularsociety.org
Prasugrel is now the preferred choice of P2Y12 receptor inhibitor for dual antiplatelet
therapy with Aspirin for patients undergoing coronary intervention. It is now recommended …
therapy with Aspirin for patients undergoing coronary intervention. It is now recommended …
Pretreatment with P2Y12 Inhibitors in Non–ST-Segment–Elevation Acute Coronary Syndrome: An Outdated and Harmful Strategy
Collet et al Pretreatment in NSTE-ACS 1905 bleeding events among patients receiving PCI.
9 However, the timing of loading was not tested in these pivotal trials. It remained a matter of …
9 However, the timing of loading was not tested in these pivotal trials. It remained a matter of …